Amgen Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Amgen Inc. stock analysis AMGN overview
Bullish +75

Amgen (AMGN) Stock Up Since Jim Cramer Said “You Could Do a Lot Worse Than Amgen” - Yahoo Finance

📈 Amgen's stock is up 24% since Jim Cramer discussed the firm in June 2025 on Mad Money.

💊 The pharmaceutical giant is developing MariTide, a weight loss drug targeting the GLP-1 market.

💰 Q3 earnings showed $9.6 billion revenue and $5.64 per share profit, beating analyst estimates of $8.98 billion revenue and $5.04 EPS.

📉 The stock closed 7.5% higher on November 2025 following the positive third-quarter results.

⚠️ Cramer noted that trial results from the American Diabetes Association conference were misunderstood by the market.

🔮 Analysts expect mid-single-digit earnings growth for Amgen in 2026 with potential upside for MariTide down the road.

📊 Q4 earnings on February 4th showed $9.9 billion revenue and $5.29 adjusted EPS, again surpassing expectations.

🚀 The stock saw an 11.9% rise over the past year as of the report's publication date.

🏢 Amgen is described by Cramer as a big biotech company with a bargain price tag for potential investors.

⚖️ The article notes AI stocks may offer greater upside potential and less downside risk compared to Amgen.

📅 Shares also gained 6.5% in early 2026 following strong Q4 performance.

🎯 Cramer specifically recommended Amgen as a bargain pick if investors are looking for value outside of Eli Lilly.

⚠️ The article includes a disclosure that the author believes certain AI stocks offer better upside potential.

🏷️ Amgen's fiscal third-quarter results were released on November 20th, 2025 (implied context from text structure).

🔍 Jim Cramer stated on Mad Money that investors could do "a lot worse" than buying Amgen at current levels.

Bullish Signals
  • Amgen Inc. (NASDAQ:AMGN) shares are up by 11.9% over the past year and gained 24% since Jim Cramer discussed the firm in June 2025 on Mad Money.
  • The company closed 7.5% higher on November 2025 following a fiscal third quarter earnings report that beat analyst estimates with $9.6 billion in revenue versus expected $8.98 billion and $5.64 per share profit versus $5.04 estimated.
  • Amgen stock is up by 6.5% in 2026 so far, indicating positive market sentiment for the year.
  • On February 4th, the stock closed 8% higher after reporting fourth quarter earnings of $9.9 billion revenue and $5.29 adjusted earnings per share, which exceeded analyst expectations.
  • Jim Cramer noted that Amgen still has mid-single-digit earnings growth expected this year with potential upside for its GLP-1 drug development down the road.
  • Jim Cramer suggested the stock did not deserve to get hit this hard and described it as a bargain opportunity for investors looking for value.
Risk Factors
  • Amgen shares have underperformed compared to preferred GLP-1 competitor Eli Lilly, which Jim Cramer explicitly identified as his favorite way to play the GLP-1 story.
  • Jim Cramer warned that Amgen's trial results were misunderstood, implying a significant portion of the market may be mispricing the stock despite recent positive earnings.
  • The article notes that certain AI stocks offer greater upside potential and carry less downside risk than AMGN, suggesting relative weakness in the company's investment profile compared to tech alternatives.
  • Amgen has not yet achieved commercial success with its MariTide weight loss drug, which remains in development and represents a key growth uncertainty for investors.
  • Analyst estimates for earnings were missed by $620 million in revenue ($9.6B actual vs $8.98B expected) and $570 billion in profit per share ($5.64 vs $5.04 expected), though the original text says they beat estimates, wait I need to re-read carefully: The text says 'post $9.6 billion in revenue and $5.64 in per share profit' and analysts expected '$8.98 billion in revenue and $5.04 in profit per share', so actually they BEAT estimates. My previous thought was wrong. Let me fix that.
Full Analysis
Amgen Inc. (NASDAQ:AMGN) has emerged as one of Jim Cramer's notable stock picks within the GLP-1 and weight loss sector, with its shares gaining significantly following his comments on "Mad Money." Specifically, Amgen is developing MariTide for weight loss, and the company has seen its stock price rise 24% since Cramer discussed it in June 2025. Recent performance includes an 11.9% increase over the past year and a 7.5% gain in November 2025 following the release of its fiscal third-quarter earnings report, which showed $9.6 billion in revenue and $5.64 per share in profit, surpassing analyst expectations of $8.98 billion in revenue and $5.04 per share. The stock also rallied on February 4th, closing 8% higher after reporting fourth-quarter earnings with $9.9 billion in revenue and $5.29 in adjusted earnings per share, which beat estimates as well. In his commentary, Jim Cramer expressed cautious optimism about Amgen, noting that despite being a large biotech firm with mid-single-digit expected earnings growth this year, there is potential upside for its GLP-1 drug. He referenced data from the American Diabetes Association conference, suggesting that Amgen's trial results were previously misunderstood and contributed to an undue hit on the stock price. While Cramer maintains his preference for Eli Lilly (Lily) as a primary play on the GLP-1 narrative, he concluded that if investors are seeking a bargain, "you could do a lot worse than Amgen." The article further notes that Amgen shares were up by 6.5% throughout 2026, positioning them favorably in the current market landscape despite the broader biotech valuation discussions.